ArticleLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society2012
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation.
Article in Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 67 citations in OpenAlex.
- The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus.Clinical drug investigation · 2014Trial
- Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation.International journal of organ transplantation medicine · 2016Article
- Severe Cholestatic Hepatitis C in Transplant Recipients: No Longer a Threat to Graft Survival.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2015Article
- Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.Transplantation · 2015Article
- Hepatitis C: New challenges in liver transplantation.World journal of gastroenterology · 2015Review
- An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects.Clinical drug investigation · 2015Article
- Management of post transplant hepatitis C in the direct antiviral agents era.Hepatology international · 2015Review
- Hepatitis C virus reinfection after liver transplant: New chances and new challenges in the era of direct-acting antiviral agents.World journal of hepatology · 2015Review
- Recurrent HCV after liver transplantation-mechanisms, assessment and therapy.Nature reviews. Gastroenterology & hepatology · 2014Review
- Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future.World journal of gastroenterology · 2014Review
- Recurrent hepatitis C after liver transplant.World journal of gastroenterology · 2014Review
- Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents?World journal of gastroenterology · 2014Review
- Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances.Journal of clinical and translational hepatology · 2014Review
- Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.Journal of hepatology · 2014Review
- Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.Molecular diagnosis & therapy · 2014Review
- Treatment decisions and contemporary versus pending treatments for hepatitis C.Nature reviews. Gastroenterology & hepatology · 2013Review
- Current and future therapies for hepatitis C virus infection.The New England journal of medicine · 2013Review
- Daclatasvir: potential role in hepatitis C.Drug design, development and therapy · 2013Review
- Novel drugs in the management of difficult-to-treat hepatitis C genotypes.Hepatic medicine : evidence and research · 2013Review
- Recurrence of hepatitis C after liver transplantation.Annals of gastroenterology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
A recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) can lead to accelerated allograft injury and fibrosis. The aim of this article is to report the first ever use of daclatasvir (DCV; also known as BMS-790052), a potent orally administered nonstructural 5A replication complex inhibitor, in combination with peginterferon α (PEG-IFNα) and ribavirin in an LT recipient. A 49-year-old female developed a severe recurrent HCV genotype 1b infection 4 months after transplantation with severe cholestasis on biopsy, an HCV RNA level of 10,000,000 IU/mL, an alkaline phosphatase level of 1525 IU/mL, and a total bilirubin level of 8.4 mg/dL. Despite partial virological suppression with PEG-IFNα and ribavirin, progressive allograft failure ensued and culminated in retransplantation at 9 months. Three months after the second transplant, DCV (20 mg/day), PEG-IFNα2a (180 μg/week), and ribavirin (800 mg/day) were prescribed for early recurrent cholestatic HCV. Serum HCV RNA became undetectable at week 3 of treatment and remained undetectable during 24 weeks of triple therapy and during the posttreatment follow-up. DCV was well tolerated, and the trough drug levels were within the targeted range throughout the treatment. The cyclosporine trough levels were also stable during and after therapy. In conclusion, the lack of anticipated drug-drug interactions between DCV and calcineurin inhibitors and the potent antiviral efficacy of DCV make this agent (in combination with PEG-IFN and ribavirin) an attractive antiviral regimen worthy of further study in LT recipients with recurrent HCV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.